Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

Moderna intends to engage with regulatory authorities for regulatory submissions. Management intends to market mRNA-1083 by 2025. Year to date, Moderna's shares have surged 49.4% against the industry's 5.9% fall. Image Source: Zacks Investment Research Last year, Moderna provided a positive interim update from a phase III immunogenicity study (P303) on mRNA-1010 in older adults. Data from the study showed that mRNA-1010 elicited higher immune responses across all four A and B strains of influenza than GSK's ...